insights_auto
Why is SCNI down 2,22%?
Dive Deeperchevron_right
SCNI:NASDAQ
Scinai Immunotherapeutics Ltd - ADR
0,44 US$
arrow_downward
-2,22%(-0,0100) 1D
0,43 US$
arrow_downward
-2,27% (-0,010)bedtimeAfter hours
Closed: 6 ნოე, 16:00:00 GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SCNI...
Open
0,45 US$
High
0,49 US$
Low
0,43 US$
Mkt. cap
1,34 მლნ.
Avg. vol.
2,32 მლნ.
Volume
13,13 ათ.
52-wk high
13,00 US$
52-wk low
0,39 US$
EPS
-2,80 US$
Beta
2,27
Shares outstanding
706,59 ათ.
No. of employees
45
Open
0,45 US$
High
0,49 US$
Low
0,43 US$
Mkt. cap
1,34 მლნ.
Avg. vol.
2,32 მლნ.
Volume
13,13 ათ.
52-wk high
13,00 US$
52-wk low
0,39 US$
EPS
-2,80 US$
Beta
2,27
Shares outstanding
706,59 ათ.
No. of employees
45
News stories
From web sources and news partners
Yahoo Finance Singapore
·
1 დღის წინ
Scinai Reports Significant Revenue Growth in First Nine Months of 2026 as CDMO Business Expands
Profile
BiondVax Pharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on developing and manufacturing immunotherapeutic products, primarily for the treatment of infectious diseases and autoimmune diseases.
In collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Göttingen, both in Germany, BiondVax develops nanosized antibody therapies for diseases such as COVID-19, asthma and psoriasis. Wikipedia
About Scinai Immunotherapeutics Ltd - ADR